Detected ·
Khartis Therapeutics, Inc.
$50M—
Khartis Therapeutics, Inc. emerges from stealth with $95M in total funding, including a new $50M Series B, to advance the first oral, selective IGF-1R inhibitor for thyroid eye disease (TED).
- Website
- —
- Amount
- $50 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-08-14 08:03:33 UTC
- Signal ID
- 49342de1-5057-4920-bf02-8adcf3cf160b
As the API returns it
{
"id": "49342de1-5057-4920-bf02-8adcf3cf160b",
"created_at": "2026-08-14T08:03:33.929717Z",
"company_name": "Khartis Therapeutics, Inc.",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/khartis-therapeutics-inc",
"event_type": "funding",
"funding_amount": 50000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Khartis Therapeutics, Inc. emerges from stealth with $95M in total funding, including a new $50M Series B, to advance the first oral, selective IGF-1R inhibitor for thyroid eye disease (TED).*"
}